I agree. LT hold for me too. This will get traded by charts and...

First 12 Last

Share
Profile

Follow
candlestix

331 Posts.

44

30/10/18

11:25

Post #: 36311683
Share

Originally posted by zdog13 ↑

There are a lot of other avenues other than the USA that’s ave the potential to be a game changer also all IMO

The Microsoft story will put this on the radar of big data investors as well as AI institutions

The NHS trial in the UK could be huge.

Further adoption across regional screening programmes in NZ has high potential.

Further uptake in the USA - 3% last year and on track for 9% this year. That’s is great market penetration in a year.

The churn is the number I’m watching. This to me is an indication of how much technicians can’t do without the service. If this stays low - while maker penetration increases what will the SP be at 25% of the USA market? Will this put VHT with an ARR on circa $20M per year as a SAS company. When will that happen. I believe within 3 years.

What market penetration number will this product start selling itself? I believe 25% is this number at which it becomes the new normal

LT hold for me. However the shares are tightly held. I see liquidity being an issue. The price has the potential to swing as it always has, until such a time where price appreciates and liquidity takes care of itself

Expand

I agree. LT hold for me too. This will get traded by charts and pimped for the meantime but long term it's only going north. Product itself is an absolute winner and once again I'm filthy for not putting more into this when I saw it. I thought it would go down after my first buy which is what usually happens and I intended to keep average down but it only went up. Ha ha. If it dips down then great. I'll take some more!

VHT Price at posting: $1.29 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

PAM

PAM secures high-grade Chilean copper play in strong territory

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa